according to the manufacturerís instruction attached to the kit.
Bio-Radís FUNGITESTô Kit was used as a screening method for antifungal susceptibility testing of 79 C. albicans isolates. Six antifungal agents were studied at two different concentrations in modified RPMI 1640 medium. The breakpoints used were 2 and 8 mg/L for amphotericin B and 2 and 32 mg/L for flucytosine. In the case of azole drugs, these values were as follows: 0.5 and 8 mg/L for miconazole, 0.5 and 4 mg/L for both ketoconazole and itraconazole and the highest concentrations for fluconazole ñ 8 and 64 mg/L. Recovering 2 colonies from Sabouraud medium after 24-48 h incubation at 37 O C, a fungal cell suspension, with turbidity equivalent to 1 McFarland, was prepared in 3 mL of sterile water. Next, 100 µL of the suspension was placed in 1.9 mL of sterile water and mixed carefully. Using an automatic pipette 20 µL of the cell suspension was added into a vial, included in the kit, with the Suspension Medium to obtain 1 × 10 3 CFU/mL. Using the pipette, 100 µL of the suspension was transferred into each of 8 pairs of microtubes that contained antimycotics and controls. The microtubes were covered with a parafilm and incubated at 37 O C for 48 h. The results were read visually, by observing the color change into blue or pink.
Susceptibility of a strain to a given drug was shown by the blue color in both corresponding wells. The color change into pink in the first well and blue in the second indicated intermediate susceptibility to amphotericin. The pink color in both wells, corresponding to two different concentrations of the same drug, showed the resistance of a strain to the drug (3) (4) (5) .
In the next stage of our study, additional tests will be carried out with some antifungal agents according to the CLSI and EUCAST for comparative purposes. We plan to perform E-tests and then MIC (Minimal Inhibitory Concentration) and MFC (Minimal Fungicidal Concentration) of these drugs by the microdilution broth method, using their twofold dilutions in RPMI 1640 broth with MOPS prepared in 96-well polystyrene plates.
RESULTS
The assessment of the drug resistance of 79 C. albicans isolates showed that the total of 68 (86.07%) strains were susceptible to all the examined antimycotics ñ those strains were described as S (susceptible). Moreover, all the examined strains were susceptible to two studied antimycotics: amphotericin B and flucytosine. In the individual age groups, the percentage of the C. albicans iso- lates susceptible to all the studied antimycotics varied from 76.1% to 95%. The isolates with a decreased susceptibility ñ phenotype I (intermediate) were 5-20% of all the studied isolates in the individual age groups; the isolates with a decreased susceptibility as well as resistance ñ phenotype R (resistant) ñ 5% and those showing resistance ñ 5%. The highest percentage of isolates with a decreased susceptibility was found in group 1 ñ 20% and 3 ñ 14%. The presence of drug-resistant strains was detected only in the oldest age group (Figure 1) .
DISCUSSION
Increasing resistance of Candida spp. to the generally used antimycotics such as nystatin, fluconazole, miconazole, itraconazole, and ketonazole, constitutes a serious problem in both local and general treatment of patients with diagnosed mycosis (6) (7) (8) (9) . The analysis of drug susceptibility of C. albicans and non-Candida albicans strains isolated from the hands of people without any symptoms of disease over a 16-year period in Poland showed increased C. albicans and non-Candida albicans strains resistance to commonly used antifungal chemotherapeutics, mainly imidazole. Researchers found a clear rise in susceptibility of C. albicans and non-Candida albicans strains to several studied antifungals: 5-fluorocytosine, amphotericin B, miconazole, ketoconazole, itraconazole, and fluconazole (10) . The studies by Miskiewicz et al. on the prevalence of oral candidiasis in patients with prosthetic stomatopathy made it possible to evaluate, at the same time, the resistance of C. albicans isolated from dentures to antifungal drugs generally used by dentists. All the cultured C. albicans strains were susceptible to econazole, clotrimazole, miconazole, and nystatin. The resistance of C. albicans to fluconazole was 100%, to ketoconazole ñ 83.3%, and to natamycin ñ 75%. The cited data point to the co-occurrence of resistance to the most commonly used antifungal drugs, i.e. fluconazole, natamycin, and ketoconazole (11) . Similarly, in an Indian study, where a hundred and twenty clinical isolates of C. albicans from various clinical specimens were tested for susceptibility against four antifungal agents: fluconazole, itraconazole, amphotericin B, and ketoconazole, a significant increase of drug resistance in clinical isolates of C. albicans was observed (12) (13) . According to other authors, C. albicans isolates obtained from various clinical specimens were susceptible to amphotericin B (88.8%) and azole drugs: fluconazole, itraconazole, clotrimazole, and voriconazole (25.5%) (14) .
The present study determined the presence of 6 drug resistance C. albicans strains-isolates from the oral cavity of healthy children and adolescents: the greatest number of strains represented the phenotypes corresponding to a decreased susceptibility or resistance to itraconazole This agrees with numerous literature reports stating that the problem of the resistance of yeast-like fungi, including those colonizing the oral cavity, to azole drugs concerns mainly itraconazole (15) (16) (17) (18) (19) . The resistance of Candida strains to antifungal drugs was found especially in isolates coming from immunodeficient patients (20) (21) (22) (23) . In addition, the results of other studies confirmed a high proportion of C. albicans in hospital infections with a very high and high resistance to fluconazole and nystatin, shown by the isolates of C. albicans, as well as Candida krusei and Trichosporon beigelli (24) .
It is known that secondary resistance is associated with strains that were originally susceptible and acquired resistance through induction (or selection of natural resistant mutants) (10) . Our study showed the presence of drug resistant C. albicans strains in the oldest age group (subjects aged [15] [16] [17] [18] . This may suggest the development of secondary resistance in connection with an earlier local and/or general use of azole antifungals.
As the resistance of C. albicans to antifungal drugs commonly used in local and general treatment is increasing, it is necessary to look for simple and adverse affects-free prophylactic and therapeutic means to counteract the increase (11) . In the case of oral cavity mycoses, an alternative to conventional antimycotics may be chlorhexidine which, as research confirmed, shows antifungal activity in vivo and in vitro (25) .
CONCLUSIONS
Phenotypic diversity (drug resistance types) of the studied isolates indicates a wide range of adaptation possibilities enabling colonization of various ecological niches in the oral cavity ecosystem. The presence of C. albicans strains intermediate or resistant to azole drugs among the tested isolates may be due to the overuse of that drug group in general therapy and the oral cavity treatment.
